Navigation Links
Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
Date:12/7/2007

SEATTLE, Dec. 7 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has promoted Mark Frohlich, M.D. to the position of senior vice president of clinical affairs and chief medical officer. Dr. Frohlich, a urologic oncologist with over a decade of oncology drug development and patient treatment experience in the public and private sectors, was instrumental to the filing of the company's Biologics License Application (BLA) for PROVENGE(R) (sipuleucel-T) and has also had responsibility for monitoring the progress of the company's ongoing Phase 3 IMPACT trial (D9902B), a pivotal trial for Dendreon, the results of which could support the licensure of PROVENGE. Dr. Frohlich was promoted from the position of vice president of clinical affairs.

"Mark has been an exemplary leader who has led Dendreon's clinical efforts during a very active time for the organization with the ongoing regulatory approval process of PROVENGE -- a process which Mark and the rest of our team remain committed to seeing through to the approval of this promising immunotherapy for prostate cancer," stated Mitchell H. Gold, M.D., president and chief executive officer of Dendreon. "We are fortunate to have someone with Mark's expertise at the helm of our clinical team with the depth of his experience in oncology as well as his direct patient experience."

Prior to joining Dendreon in 2005, Dr. Frohlich was vice president and medical director at Xcyte Therapies where he oversaw its medical affairs operations. At Xcyte, he led the clinical development program for an autologous activated T cell therapy for the treatment of cancer, infection and immunodeficiency. Before that, he was an assistant professor in the Division of Hematology/Oncology at the University of California, San Francisco, where he specialized in urologic oncology and was active in laboratory, translational and clinical research. While at the University of California, San Franc
'/>"/>

SOURCE Dendreon Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
3. Dendreon Secures $130 Million Committed Equity Financing Facility
4. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
5. Dendreon Reports Third Quarter 2007 Financial Results
6. Enzyme promotes fat formation
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
9. Alba Therapeutics Appoints Dr. Betsy Van Parijs as Its Senior Vice President, Clinical Development and Medical Affairs
10. Senior Research Analyst Richard Evans Joins AVOS Life Sciences
11. Schering-Plough Announces Pricing of Senior Notes Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... D.C. (PRWEB) September 18, 2014 On ... Durbin and Sen. Jim Risch for National Lab Day ... projects from across the national laboratory system. Durbin and ... which aims to increase awareness of the reach of ... technologies and discoveries to address some of our nation's ...
(Date:9/18/2014)... 2014 Research and Markets has ... Industry Report 2014" report to their offering. ... is a professional and in-depth study on the current ... The report provides a basic overview of the industry ... human albumin market analysis is provided for the international ...
(Date:9/18/2014)... -- U.S. biotech company Kultevat has strengthened its ... developed by the Donald Danforth Plant Science Center ... applications in production of natural rubber in Taraxicum ... under the direction of Roger Beachy , Ph.D., ... the Danforth Plant Science Center, and is used to ...
(Date:9/18/2014)... Sept. 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... announced concurrent but separate underwritten offerings of 10,000,000 shares ... public of $2.00 per share, for expected gross proceeds ... A Convertible Preferred Stock at a price to the ... of $20 million. Each share of Series A Convertible ...
Breaking Biology Technology:Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Kultevat obtains license of gene switch technology 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... - Jason Smith acknowledges he's on a personal mission. The ... of the Peak Ridge Capital Group, wants to bridge the gap ... passion for investing in innovative Midwestern technology companies is one of ... in the morning and it is one of the first things ...
... Wis. - Broadlook Technologies , an Internet ... as the firm's chief operations officer. , ,Meier brings ... sectors, and he will be responsible for helping the ... programs. , ,"I believe in Greg, and he believed ...
... Madison, Wis. - A University of Wisconsin-Madison ... return in the nation, according to BusinessWeek 's latest ... class of 2006 paid $186,800 for their MBAs and started ... even in four and a half years, not counting lost ...
Cached Biology Technology:Investor links East Coast funds to Midwest tech 2Investor links East Coast funds to Midwest tech 3UW-Madison MBA program ranked among best for investment return 2
(Date:9/19/2014)... A new study shows that legume plants regulate ... cytokininssignaling molecules that are transmitted through the plant ... the number of bacteria-holding nodules in the roots. ... the National Institute for Basic Biology, the Graduate ... Center for Sustainable Resource Science in Japan. ...
(Date:9/18/2014)... into the Crimean-Congo hemorrhagic fever virus (CCHFV), a tick-borne ... similar to that caused by Ebolavirus, has identified new ... the potential to lead to novel targets for therapeutic ... reported in a paper published today in the journal ... the Texas Biomedical Research Institute and their colleagues, represents ...
(Date:9/18/2014)... that prompts millions of Americans to undertake jaunts into the ... a little longer within a century, according to new research. ... areas of the United States as summer temperatures linger later ... Global Ecology and Biogeography . For instance, the paper ... tree of New Hampshire could change color one to ...
Breaking Biology News(10 mins):For legume plants, a new route from shoot to root 2Research milestone in CCHF virus could help identify new treatments 2Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4
... interplay of brain chemicals which help us pay attention in ... By changing the way neurons respond to external stimuli we ... strength of a neuronal response, they can also affect the ... Thiele, Professor of Visual Neuroscience explains: "When you communicate with ...
... can detect molecular variants in chemical mixtures greatly ... important, though time-consuming, processes in analytical chemistry. ... post-doctoral researcher David Patterson, Professor of Physics John Doyle ... Laser Science (CFEL) in Hamburg, Germany developed a system ...
... endanger the whole organism, as they may lead to ... Munich now report how byproducts of respiration cause mispairing ... in our cells controls the form and function of ... this are encoded in the linear sequence of the ...
Cached Biology News:Detecting mirror molecules 2Detecting mirror molecules 3DNA damage: The dark side of respiration 2
Comp Dim: chamber diam. depth 20 2.8 mm chamber maximum volume 720 μL...
... vitro diagnostic assays, all EIA/RIA plates are ... binding, high optical clarity and low background ... of the Certified Surface Chemistry Programme, which ... QA release specifications. Linkage: This CLS number ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
Biology Products: